Have a Claim?

Click here for a confidential contact or call:

1-212-350-2764

May 31, 2019

Posted  May 31, 2019

Generic drug maker Heritage Pharmaceuticals, Inc. has entered into a deferred prosecution agreement for criminal antitrust charges, admitting that it conspired to fix prices, rig bids, and allocate customers for the diabetes drug glyburide.  Heritage will pay a $225,000 criminal penalty and has agreed to cooperate in ongoing antitrust investigations.  In addition, Heritage will pay $7.1 million to resolve allegations under the False Claims Act that the company paid and received unlawful remuneration under the Anti-Kickback Statute through its arrangements with other generic drug makers regarding prices, supply, and allocation of customers for drugs including glyburide, hydralazine, and theophylline.  DOJ; USAO ED Pa

Tagged in: Anti-Kickback and Stark, Bribery and Bid-Rigging, Drug and DME Pricing, FCA Federal, Pharma Fraud,

Newsletter

Subscribe to receive email updates from the Constantine Cannon blogs

Sign up for: